A Phase 1, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects With Lymphoid Hematological Malignancies
Phase of Trial: Phase I
Latest Information Update: 21 Jun 2017
At a glance
- Drugs CB 5083 (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Cleave Biosciences
- 15 Jun 2017 Status changed from recruiting to discontinued.
- 26 Jul 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018.
- 26 Jul 2016 Status changed from active, no longer recruiting to recruiting.